Orphazyme Financials
| ORPHA Stock | DKK 915.00 9.90 1.07% |
Orphazyme |
Understanding current and past Orphazyme Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Orphazyme's financial statements are interrelated, with each one affecting the others. For example, an increase in Orphazyme's assets may result in an increase in income on the income statement.
Please note, the presentation of Orphazyme's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Orphazyme's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Orphazyme's management manipulating its earnings.
Orphazyme Stock Summary
Orphazyme competes with Zealand Pharma, Ambu AS, and Genmab AS. Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.| Instrument | Denmark Stock View All |
| Exchange | Copenhagen Exchange |
| ISIN | DK0060910917 |
| Business Address | Ole MaalOees Vej |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.orphazyme.com |
| Phone | 45 39 17 82 72 |
| Currency | DKK - Danish Krone |
You should never invest in Orphazyme without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Orphazyme Stock, because this is throwing your money away. Analyzing the key information contained in Orphazyme's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Orphazyme Key Financial Ratios
Orphazyme's financial ratios allow both analysts and investors to convert raw data from Orphazyme's financial statements into concise, actionable information that can be used to evaluate the performance of Orphazyme over time and compare it to other companies across industries.| Return On Equity | -4.87 | |||
| Return On Asset | -1.33 | |||
| Target Price | 108.0 | |||
| Beta | 0.82 | |||
| Z Score | -2.7 |
Orphazyme Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orphazyme's current stock value. Our valuation model uses many indicators to compare Orphazyme value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orphazyme competition to find correlations between indicators driving Orphazyme's intrinsic value. More Info.Orphazyme AS is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Orphazyme by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Orphazyme's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Orphazyme AS Systematic Risk
Orphazyme's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Orphazyme volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Orphazyme AS correlated with the market. If Beta is less than 0 Orphazyme generally moves in the opposite direction as compared to the market. If Orphazyme Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Orphazyme AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Orphazyme is generally in the same direction as the market. If Beta > 1 Orphazyme moves generally in the same direction as, but more than the movement of the benchmark.
Orphazyme November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Orphazyme help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Orphazyme AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Orphazyme AS based on widely used predictive technical indicators. In general, we focus on analyzing Orphazyme Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Orphazyme's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.99 | |||
| Information Ratio | 0.0462 | |||
| Maximum Drawdown | 32.6 | |||
| Value At Risk | (6.54) | |||
| Potential Upside | 7.86 |
Complementary Tools for Orphazyme Stock analysis
When running Orphazyme's price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |